Candel Therapeutics, Inc. (NASDAQ: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of Maria Ostrovsky as General Counsel, effective November 3.
Ms. Ostrovsky has 20 years of legal experience, most of it in the life sciences industry. She will oversee Candel’s legal and compliance functions, including corporate governance, and report to Candel’s President and Chief Executive Officer.
Ostrovsky joins Candel at a pivotal stage in the Company’s evolution, as it advances its clinical pipeline, prepares for a planned BLA submission for aglatimagene besadenovec (aglatimagene) in intermediate- to high-risk localized prostate cancer in the fourth quarter of 2026, and builds the capabilities needed to support potential commercialization, if approved.
“Maria brings a highly relevant combination of legal, compliance, global product launch and strategic transaction experience,” said CEO Paul Peter Tak. “She has supported oncology launches in the United States and globally, built a healthcare compliance program at a commercial-stage biotech, and helped guide acquisition diligence, post-merger integration and international operations.
“As we prepare for our planned BLA submission and potential commercialization of aglatimagene, if approved, Maria will help us build scalable legal, governance and compliance capabilities for Candel’s next stage of growth.”
CNDL shares gathered 35 cents Thursday to $8.72.
Related Stories
